BioCentury | Feb 25, 2017
Product Development

Getting the message

...disease vaccines in green and functional protein therapies in gold. (A) In January, CureVac announced CV9104...
...is strong enough for efficacy. At the JPMorgan presentation, Hoerr reported that a second vaccine, CV9104...
...of improving overall survival in a Phase IIb trial to treat castration-resistant prostate cancer (CRPC). CV9104...
BioCentury | Feb 24, 2017
Product R&D

Two firsts for Zika

...to cause mutations. The most advanced RNA vaccine is CureVac AG ’s prostate cancer candidate CV9104...
BioCentury | Jan 13, 2017
Clinical News

CV9104: Ph IIb data

...trial in 197 chemotherapy-naïve, asymptomatic or minimally symptomatic patients with metastatic CRPC showed that intradermal CV9104...
...at the JPMorgan Healthcare Conference in San Francisco. The company said it will consider evaluating CV9104...
..."much more potent immune response" seen in preclinical studies. CureVac GmbH , Tübingen, Germany Product: CV9104...
BioCentury | Jan 12, 2017
Clinical News

CureVac's prostate cancer vaccine fails in Phase IIb trial

...CureVac AG (Tuebingen, Germany) said its lead vaccine candidate CV9104 failed to improve overall survival in...
...also said progression-free survival, a secondary endpoint, was similar in the trial's two arms comparing CV9104...
...checkpoint inhibitors, based on a "much more potent immune reponse" seen in preclinical combination studies. CV9104...
BioCentury | Nov 18, 2016
Finance

Diversifying CureVac

...to raise significant cash in the future. CureVac’s lead program is the mRNA-based cancer vaccine CV9104...
BioCentury | Nov 8, 2016
Financial News

CureVac raises $29.5M

...$360 million since it was launched in 2000. The company's lead candidate, prostate cancer vaccine CV9104...
...targeting six antigens overexpressed in prostate cancer (see BioCentury Extra, Nov. 3, 2015) . Jaime De Leon CV9104 CureVac...
BioCentury | Nov 4, 2015
Financial News

CureVac raises $110M in private placement

...data in 2H16 from a Phase IIb study of its lead candidate, prostate cancer vaccine CV9104...
BioCentury | Sep 29, 2014
Finance

CureVac bet paying off

...of Hopp's big bet: showing an overall survival benefit in a Phase IIb trial of CV9104...
...be announced. He said once data are available, the company will decide whether to take CV9104...
BioCentury | Mar 17, 2014
Company News

CureVac infectious news

...temperature and inadvertent freezing. CureVac has several RNActive immunotherapies in clinical testing for cancer, including CV9104...
BioCentury | Dec 23, 2013
Clinical News

CV9104: Phase I/IIb completed enrollment

...double-blind, placebo-controlled, European Phase I/IIb trial evaluating intradermal CV9104. CureVac GmbH , Tuebingen, Germany Product: CV9104...
Items per page:
1 - 10 of 11